CC
BNR

Casdin Capital’s Burning Rock Biotech BNR Stock Holding History

Casdin Capital’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-84,715
Closed -$22.8M – 56
2021
Q1 		$22.8M Sell
84,715
-107,500
-56% -$32.7M 0.68% 30
2020
Q4 		$44.4M Hold
192,215
– – 1.32% 19
2020
Q3 		$48.2M Buy
192,215
+19,136
+11% +$4.53M 2.16% 14
2020
Q2 		$46.7M Buy
+173,079
New +$47.4M 2.77% 11

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Casdin Capital's BNR Position: Q2 2021 in Review

Casdin Capital sold out of Burning Rock Biotech (BNR) in Q2 2021, closing a stake of 84,715 shares — an estimated $22.8M sold.

Casdin Capital first reported a position in BNR in Q2 2020 and held it in 4 quarters. The position peaked at $48.2M in Q3 2020. 85 funds tracked by Wall St. Rank hold BNR as of Q2 2021.

  • Casdin Capital reported no remaining Burning Rock Biotech position as of Q2 2021 after selling out during the quarter.
  • Casdin Capital sold 84,715 Burning Rock Biotech shares in Q2 2021, an estimated $22.8M.
  • Casdin Capital first reported a position in Burning Rock Biotech in Q2 2020 and held it in 4 quarters.
  • Casdin Capital's Burning Rock Biotech position peaked at $48.2M in Q3 2020.
  • 85 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2021.

Based on Casdin Capital's 13F filing for Q2 2021, filed 16 Aug 2021.